Cue Biopharma, Inc. (CUE) Dividend History

Company News

• High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds

  Despite regulatory challenges and budget cuts, the oncology market is projected to reach US$900 billion by 2034, with several biotech companies advancing innovative cancer therapies and demonstrating promising clinical trial results.

  Benzinga

  Featured Companies: ALLO CATX ONCY VSTM
• Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

  Cue Biopharma received positive feedback from the FDA on its pre-IND briefing document for CUE-401, a first-in-class bispecific molecule designed to induce and expand regulatory T cells for the treatment of autoimmune diseases. The company plans to file an IND for CUE-401 after completing final enabling studies.

  GlobeNewswire Inc.
• Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?

  Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

  Zacks Investment Research

  Featured Companies: XOMA
• Cue Biopharma, Inc. (CUE) Soars 8.3%: Is Further Upside Left in the Stock?

  Investing.com